LOS ANGELES, Sept. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN)
announced that it has filed its Form 25 with the Securities and Exchange
Commission effecting the withdrawal of trading of its common stock on the
American Stock Exchange ('AMEX'). The last day that Signalife's common stock
will trade on AMEX will be Friday, September 12, 2008. Signalife expects that
the company's common stock will be available for quotation on both the
Over-The-Counter Bulletin Board and the Pink Sheets commencing upon the
opening of market on Monday, September 15, 2008. Pursuant to OTCBB policy, it
will assign a new trading symbol for Signalife's common stock following the
close of trading on AMEX on Friday, September 12, 2008. Signalife will
publicly announce the new trading symbol promptly upon receipt from the OTCBB.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring,
detection and prevention of disease through continuous biomedical signal
monitoring. Signalife uses its patented signal technology to design and
develop medical devices, therapies and/or technologies that simplify and
reduce the costs of cardiovascular disease. More information is located at
www.signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are 'forward-
looking' statements. Forward-looking statements involve known and unknown
risks, which may cause the companies' actual results in the future to differ
materially from expected results. Factors which could cause or contribute to
such differences include, but are not limited to, the failure of Signalife's
market maker to complete or timely complete the process of qualifying the
shares for quotation on the OTCBB, failure to complete the development and
introduction of heart monitoring and other biomedical devices incorporating
the companies' technology and procure market acceptance for these products,
failure to obtain federal or state or governmental or international regulatory
approvals governing heart monitoring and other biomedical devices
incorporating the technology, failure to obtain import and export capabilities
in the various countries containing buyers and resellers and hospitals and
clinics and doctors for the devices, inability to obtain physician, patient or
insurance acceptance of or for heart monitoring and other biomedical
incorporating of the technologies, and the unavailability of financing to
complete management's plans and objectives, including the development of heart
monitoring and other biomedical and information solutions incorporating the
companies' technologies. These risks are qualified in their entirety by
cautionary language and risk factors set forth and to be further described in
Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
